What is the difference between Zepbound and Wegovy?
Last updated September 3, 2026.
Zepbound is tirzepatide, a dual GIP and GLP-1 receptor agonist; Wegovy is semaglutide, a GLP-1-only agonist. Both are weekly injections approved for chronic weight management in adults with obesity, or overweight with a weight-related condition. The dual-receptor action of tirzepatide is the meaningful pharmacological difference. In Zepbound's label trials, mean weight loss at 72 weeks was 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% on placebo. In Wegovy's label trial, mean loss was 14.9% on 2.4 mg versus 2.4% on placebo at 68 weeks. These were not head-to-head studies, so treat the gap as directional. Side effect profiles are similar and mostly gastrointestinal: nausea, vomiting, diarrhea, and constipation, worst during dose escalation. Both carry a boxed warning about thyroid C-cell tumors seen in rodents and are avoided with a personal or family history of medullary thyroid carcinoma or MEN 2. Cost and coverage often decide in practice, since insurers treat the two drugs differently.
What to do
- Compare on your goals: if maximum average weight loss is the priority, Zepbound's trial numbers are higher; if cardiovascular event reduction matters, Wegovy has an approval for reducing heart attack and stroke risk.
- Check coverage first: formularies frequently cover one and not the other.
- Expect similar side effects: both cause GI symptoms during dose escalation.
- Ask your prescriber: diabetes status, other medications, and your history shape which fits you.
Related questions
- What is the difference between Ozempic and Wegovy?
- What is the difference between Mounjaro and Zepbound?
- Can I get GLP-1 medication without diabetes?
- What are the side effects of GLP-1 drugs?